IN2014CN02959A - - Google Patents
Info
- Publication number
- IN2014CN02959A IN2014CN02959A IN2959CHN2014A IN2014CN02959A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A IN 2959CHN2014 A IN2959CHN2014 A IN 2959CHN2014A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- abvdisclosed
- het
- salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002889 sympathetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552885P | 2011-10-28 | 2011-10-28 | |
| PCT/US2012/062207 WO2013063459A1 (en) | 2011-10-28 | 2012-10-26 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02959A true IN2014CN02959A (OSRAM) | 2015-07-03 |
Family
ID=48168585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2959CHN2014 IN2014CN02959A (OSRAM) | 2011-10-28 | 2012-10-26 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9273040B2 (OSRAM) |
| EP (1) | EP2770995B1 (OSRAM) |
| JP (1) | JP2014532660A (OSRAM) |
| KR (1) | KR20140095067A (OSRAM) |
| CN (1) | CN103889419A (OSRAM) |
| AU (1) | AU2012328561A1 (OSRAM) |
| BR (1) | BR112014010197A2 (OSRAM) |
| CA (1) | CA2852796A1 (OSRAM) |
| IN (1) | IN2014CN02959A (OSRAM) |
| MX (1) | MX2014005068A (OSRAM) |
| RU (1) | RU2014121489A (OSRAM) |
| WO (1) | WO2013063459A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| JP6096370B2 (ja) | 2013-03-14 | 2017-03-15 | ジェネンテック， インコーポレイテッド | 置換トリアゾロピリジンとその使用方法 |
| RU2015143834A (ru) | 2013-03-15 | 2017-04-24 | Дженентек, Инк. | Замещенные бензоксазолы и способы их применения |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| AU2015242219A1 (en) | 2014-03-29 | 2016-10-06 | Lupin Limited | Sulfonamide compounds as Voltage gated sodium channel modulators |
| EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP6742331B2 (ja) * | 2015-03-02 | 2020-08-19 | アムジエン・インコーポレーテツド | 二環式ケトンスルホンアミド化合物 |
| HK1252567A1 (zh) | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| HK1255027A1 (zh) | 2015-12-18 | 2019-08-02 | Merck Sharp & Dohme Corp. | 在电压门控钠离子通道中具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代二胺-芳基磺酰胺化合物 |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US10246453B2 (en) | 2016-05-20 | 2019-04-02 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| RU2019114964A (ru) | 2016-10-17 | 2020-11-17 | Дженентек, Инк. | Терапевтические средства и способы их применения |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| UY37729A (es) * | 2017-05-11 | 2019-01-02 | Glaxosmithkline Ip Dev Ltd | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
| WO2019204740A1 (en) * | 2018-04-19 | 2019-10-24 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using azetidines |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| BR112020024729A2 (pt) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| AU2019331005B2 (en) | 2018-08-31 | 2024-03-28 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| CA3104913A1 (en) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| AU760250B2 (en) * | 1998-12-04 | 2003-05-08 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| PT1598338E (pt) | 2001-04-18 | 2009-05-08 | Euro Celtique Sa | Derivados de 1-(4-piperidinil)-1,3-di-hidro-2h-indole-2-ona e compostos relacionados como análogos de nociceptina e ligandos orl-1 para o tratamento da dor |
| EP1467986A1 (en) | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| KR20080015102A (ko) * | 2005-05-10 | 2008-02-18 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| WO2006133459A1 (en) * | 2005-06-09 | 2006-12-14 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| NZ569694A (en) | 2005-12-21 | 2011-06-30 | Vertex Pharma | Heterocyclic derivatives as modulators of ion channels |
| JP5460589B2 (ja) * | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| CA2734651A1 (en) | 2008-08-21 | 2010-02-25 | Richter Gedeon Nyrt. | Methods for treating neuropathic pain |
| ES2536191T3 (es) | 2009-01-12 | 2015-05-21 | Pfizer Limited | Derivados de sulfonamida |
| ES2619557T3 (es) * | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 para uso en el tratamiento del cáncer |
-
2012
- 2012-10-26 IN IN2959CHN2014 patent/IN2014CN02959A/en unknown
- 2012-10-26 WO PCT/US2012/062207 patent/WO2013063459A1/en not_active Ceased
- 2012-10-26 KR KR1020147013911A patent/KR20140095067A/ko not_active Withdrawn
- 2012-10-26 RU RU2014121489/04A patent/RU2014121489A/ru not_active Application Discontinuation
- 2012-10-26 US US14/353,488 patent/US9273040B2/en active Active
- 2012-10-26 BR BR112014010197A patent/BR112014010197A2/pt not_active IP Right Cessation
- 2012-10-26 CA CA2852796A patent/CA2852796A1/en not_active Abandoned
- 2012-10-26 EP EP12843015.4A patent/EP2770995B1/en not_active Not-in-force
- 2012-10-26 CN CN201280052937.2A patent/CN103889419A/zh active Pending
- 2012-10-26 AU AU2012328561A patent/AU2012328561A1/en not_active Abandoned
- 2012-10-26 MX MX2014005068A patent/MX2014005068A/es not_active Application Discontinuation
- 2012-10-26 JP JP2014539066A patent/JP2014532660A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014005068A (es) | 2014-07-30 |
| US20140303143A1 (en) | 2014-10-09 |
| US9273040B2 (en) | 2016-03-01 |
| WO2013063459A1 (en) | 2013-05-02 |
| AU2012328561A8 (en) | 2014-05-01 |
| CN103889419A (zh) | 2014-06-25 |
| CA2852796A1 (en) | 2013-05-02 |
| EP2770995B1 (en) | 2019-01-02 |
| AU2012328561A1 (en) | 2014-04-17 |
| JP2014532660A (ja) | 2014-12-08 |
| RU2014121489A (ru) | 2015-12-10 |
| EP2770995A4 (en) | 2015-06-03 |
| EP2770995A1 (en) | 2014-09-03 |
| KR20140095067A (ko) | 2014-07-31 |
| BR112014010197A2 (pt) | 2017-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02959A (OSRAM) | ||
| PH12018501288A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| PH12015502615B1 (en) | Chemical compounds | |
| WO2014120808A8 (en) | Pyridone amides as modulators of sodium channels | |
| BR112015009216A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica | |
| CL2015001599A1 (es) | Compuestos derivados de (piridin o pirimidin)-(piperidina o piperazina) sustituidos o sus sales, inhibidores de la colesterol 24-hidroxilasa (ch24h); medicamento; metodo de inhibicion de la ch24h; metodo para prevenir o tratar; y uso para la prevencion o tratamiento de epilepsia, alzheimer y parkinson, entre otras enfermedades. | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| PT2822555T (pt) | Inibição da cinase 1 associada a adaptador para o tratamento da dor | |
| HK1213888A1 (zh) | 治療化合物和組合物以及其作為pkm2調節劑的用途 | |
| NZ738672A (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
| PH12015502365B1 (en) | Bace1 inhibitors | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| WO2014043252A3 (en) | Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application | |
| WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| TN2015000275A1 (fr) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| IN2012DN06061A (OSRAM) | ||
| WO2013148638A3 (en) | Compositions and methods related to inhibitors of jak kinase | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| WO2013121334A3 (en) | Agents for treating neurodegenerative disorders | |
| WO2013175347A3 (en) | Compositions and methods for treatment of respiratory disorders |